Chia Tai Tianqing Pharmaceutical Group Co., Ltd. clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 4 with minor changes only.

1. Notable

   Inhaled TQC3721 Suspension · Moderate-to-Severe Chronic…Inhaled TQC3721 Suspension · Moderate-to-Severe Chronic Obstructive Pulmonary Disease

   Primary endpoint(s) modified

   Also in this update: Recruitment opened; Trial sites reduced: 79 → 54 locations

   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3· NCT07464587· Registry history of NCT07464587 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

2. Notable

   Treatment · Moderate to Severe Crohn's Disease With Tabellvi®

   Recruitment opened

   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 4· NCT07663526· Registry history of NCT07663526 on ClinicalTrials.gov (opens the registry)

   Updated Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.